Author:
Sehouli Jalid,Papanikolaou G.,Braicu E.-I.,Pietzner K.,Neuhaus P.,Fotopoulou C.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control. 2011;18:31–43.
2. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer. 2008;44:2350–6.
3. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902–8.
4. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230–8.
5. Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Daraï E. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Res. 2010;30:4743–7.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献